Neue Optionen in der Behandlung der therapieresistenten Depression – von der Klinik zur Praxis

Literatur: – Carter B, Strawbridge R, Husain MI, Jones BDM, short R, Cleare AJ, Tsapekos D, Patrick F, Marwood L, Taylor RW, Mantingh T, de Angel V, Nikolova VL, Carvalho AF, Young AH. Int Rev Psychiatry. 2020; 32: 477–90. – Dold M, Bartova L, Kasper S. Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment. Int J Neuropsychopharmacol. 2020; 23: 440–45. – Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry 4Clin Pract. 2017; 21:13–23. – Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets Science. 2012; 338(6103): 68–72. – Kasper S, Cubała WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young A. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. 2021 (in press); https://doi.org/10.1080/15622975.2 020.1836399 – Wajs E, Aluisio L, Holder R, Daly EJ, Lane R Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB. Esketamine Nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020; 81(3): 19m12891.